
CBE ID

0618

Title

Diabetes with LDL-C greater than 100 - Use of a Lipid Lowering Agent

Project

National Voluntary Consensus Standards For Clinically Enriched Administrative Data

Endorsement Status

Endorsement Removed

Is Under Review

No

Previous Endorsement Cycle

Full Year 2009

Removal Date

Wed, 12/11/2013 - 19:00

Initial Endorsement

Thu, 12/03/2009 - 19:00

Steward

ActiveHealth Management

1.0 New or Maintenance

Maintenance

1.1 Measure Structure

Single Measure

1.3 Electronic Clinical Quality Measure (eCQM)

No

1.6 Measure Description

The percentage of patients with a diagnosis of diabetes mellitus aged 41 to 75 years, or aged 18 to 40 years with additional risk factors, whose most recent LDL-C value is more than 100 mg/dL and who are taking a lipid lowering agent.

1.7 Measure Type

Process

1.8 Level of Analysis

Clinician: Group/Practice, Clinician: Individual, Facility, Health Plan, Integrated Delivery System, Other, Population: Community, County or City, Population: Regional and State

1.9 Care Setting

Home Care, Outpatient Services

1.14 Numerator

Patients who are taking a lipid lowering agent

1.15 Denominator

Patients with a diagnosis of diabetes mellitus aged 41 to 75 years, or aged 18 to 40 years with additional risk factors, whose most recent LDL-C value is more than 100 mg/dL.

1.20 Types of Data Sources

Claims Data, Electronic Health Data, Electronic Health Records: Electronic Health Records, Instrument-Based Data, Other

6.1.2 Current or Planned Use(s)

Public Reporting, Quality Improvement (Internal to the specific organization)

6.1.3 Current Use(s)

Public Reporting, Quality Improvement (Internal to the specific organization)

Exclusions

SPECIFIC DENOMINATOR EXCLUSIONS

One of the following is correct:

1. Presence of patient data c via online PHR or telephonic nurse assessment confirming breast feeding in the past 6 months
2. If Pregnancy Loose Version Validation is confirmed for the member (see below)

General exclusions:

1. Evidence of metastatic disease or active treatment of malignancy (chemotherapy or radiation therapy) in the last 6 months;
2. Patients who have been in a skilled nursing facility in the last 3 months
3. Patients who are terminally ill or in Hospice
4. Patient or provider feedback indicating allergy, intolerance or other contraindication to lipid lowering therapy anytime in the past

Planned Use

Public Reporting, Quality Improvement (Internal to the specific organization)

Risk Adjustment

No risk adjustment or risk stratification

Steward Organization

ActiveHealth Management

Steward POC email

mvemireddy@activehealth.net